Following the discovery that NF1 deficiency confers intrinsic and acquired resistance to EGFR inhibitor in lung cancer, treatment of neurofibromin-deficient lung cancers in vitro and in xenografts with MEK inhibitory drugs (AZD-6244, CI-1040 and PD0325901) restored sensitivity to erlotinib when given in combination [110]. This evidence concerns the gene NF1 and lung carcinoma.